Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

about

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Item

http://www.wikidata.org/entity/Q58562294

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Cons: should immunotherapy be ...... f oncogene-driven lung cancer?

@en

Cons: should immunotherapy be ...... f oncogene-driven lung cancer?

@nl

type

Item

label

Cons: should immunotherapy be ...... f oncogene-driven lung cancer?

@en

Cons: should immunotherapy be ...... f oncogene-driven lung cancer?

@nl

prefLabel

Cons: should immunotherapy be ...... f oncogene-driven lung cancer?

@en

Cons: should immunotherapy be ...... f oncogene-driven lung cancer?

@nl

P1476

Cons: should immunotherapy be ...... f oncogene-driven lung cancer?

@en

P2093

Giulio Metro

http://www.w3.org/2001/XMLSchema#string

Massimo Di Maio

http://www.w3.org/2001/XMLSchema#string

P2860

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.

P304

S290-S293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/TLCR.2018.07.11

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

Suppl 3

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30393625

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

6193898

http://www.w3.org/2001/XMLSchema#string